4.8 Article

Regulatory T-cell therapy in Crohn's disease: challenges and advances

期刊

GUT
卷 69, 期 5, 页码 942-952

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2019-319850

关键词

-

资金

  1. Litwin IBD Pioneers Funding Programme at the Crohn's and Colitis Foundation [504039]
  2. Freemason's Grand Charity [SPG00268]
  3. Rosetree's Trust [A1219]
  4. Medical Research Council (MRC) Trust Clinical Research Training Fellowship [MRS00033X/1]
  5. MRC [MR/R001413/1, MR/T005564/1]
  6. Department of Health via the National Institute for Health (NIHR) comprehensive Biomedical Research Centre
  7. King's College London
  8. King's College Hospital NHS Foundation Trust
  9. MRC [G0802068, MR/M003493/1, MR/N006445/1, MR/S00033X/1, MR/T005564/1] Funding Source: UKRI

向作者/读者索取更多资源

The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据